News & Updates

NSAID use does not predispose OA patients to COVID-19 infection

10 May 2021 by

Patients with osteoarthritis (OA) can safely continue taking their nonsteroidal anti-inflammatory drugs (NSAIDs), which have been shown to have a null effect on the risk of contracting COVID-19 or all-cause mortality, as reported in a study.

NSAID use does not predispose OA patients to COVID-19 infection

10 May 2021

Allopurinol lowers hepatotoxicity risk in thiopurine users

10 May 2021 by

Use of allopurinol results in a 58-percent reduced risk of hepatotoxicity among thiopurine users, while myelotoxicity rates are not affected, according to a study. Moreover, thiopurine persistence is extended by 2.1 years in allopurinol users.

Allopurinol lowers hepatotoxicity risk in thiopurine users

10 May 2021

Updated IMvigor130 data shows OS benefit of atezolizumab for bladder cancer

10 May 2021 by

Updated analyses of the phase III IMvigor130 trial presented at AACR 2021 revealed the overall survival (OS) benefit of atezolizumab for previously untreated locally advanced or metastatic urothelial carcinoma (mUC), be it alone or with platinum/gemcitabine chemotherapy (CT).

Updated IMvigor130 data shows OS benefit of atezolizumab for bladder cancer

10 May 2021

Intranasal zavegepant shows promise for acute migraine treatment

08 May 2021 by

The novel CGRP receptor antagonist zavegepant administered intranasally effectively reduces pain and the most bothersome symptom (MBS) in patients with migraine, shows a study presented at the AAN 2021 Annual Meeting.

Intranasal zavegepant shows promise for acute migraine treatment

08 May 2021

Cannabidiol for Lennox–Gastaut syndrome takes effect within a week

08 May 2021

The effect of cannabidiol (CBD) in the treatment of patients with Lennox–Gastaut syndrome may occur within 7 days of initiation, and most adverse events resolve within a 14-week period, a study reports.

Cannabidiol for Lennox–Gastaut syndrome takes effect within a week

08 May 2021

Denosumab, alendronic acid show null effect on aortic valve calcification

07 May 2021

Both denosumab and alendronic acid fall short of reducing disease progression in patients with calcific aortic stenosis, a study has shown.

Denosumab, alendronic acid show null effect on aortic valve calcification

07 May 2021

Hormonal IUD shows potential in early endometrial cancer

07 May 2021 by

Hormonal therapy with a levonorgestrel-releasing intrauterine device (LNG-IUD) led to a high pathological complete response (pCR) rate in women with early-stage endometrial cancer, according to the feMMe trial presented at SGO 2021 Meeting.

Hormonal IUD shows potential in early endometrial cancer

07 May 2021

Severe QT prolongation rare with bedaquiline-based treatment for drug-resistant TB

07 May 2021 by

A regimen containing bedaquiline appears to be safe in the treatment of patients with rifampin-resistant tuberculosis, with severe prolongation of the QT interval occurring infrequently and requiring no permanent discontinuation of therapy, as reported in a recent study.

Severe QT prolongation rare with bedaquiline-based treatment for drug-resistant TB

07 May 2021

Apatinib-pegylated liposomal doxorubicin combo ups survival in ovarian cancer

07 May 2021 by

The addition of the oral, small-molecule tyrosine kinase inhibitor apatinib to pegylated liposomal doxorubicin (PLD) led to a significant improvement in progression-free survival (PFS) among women with platinum-resistant or refractory recurrent ovarian cancer* compared with PLD alone, according to the results of the APPROVE trial presented at SGO 2021.

Apatinib-pegylated liposomal doxorubicin combo ups survival in ovarian cancer

07 May 2021

ORZORA: Maintenance olaparib shows benefit in BRCA-mutated ovarian cancer

07 May 2021 by

Maintenance treatment with olaparib showed progression-free survival (PFS) benefit in patients with platinum-sensitive relapsed ovarian cancer (PSR OC), particularly those with somatic BRCA mutation (BRCAm), according to results of the ORZORA* trial presented at SGO 2021.

ORZORA: Maintenance olaparib shows benefit in BRCA-mutated ovarian cancer

07 May 2021

News & Updates

Filter by Specialty:

Specialty:

NSAID use does not predispose OA patients to COVID-19 infection

NSAID use does not predispose OA patients to COVID-19 infection

Allopurinol lowers hepatotoxicity risk in thiopurine users

Allopurinol lowers hepatotoxicity risk in thiopurine users

Updated IMvigor130 data shows OS benefit of atezolizumab for bladder cancer

Updated IMvigor130 data shows OS benefit of atezolizumab for bladder cancer

Intranasal zavegepant shows promise for acute migraine treatment

Intranasal zavegepant shows promise for acute migraine treatment

Cannabidiol for Lennox–Gastaut syndrome takes effect within a week

Cannabidiol for Lennox–Gastaut syndrome takes effect within a week

Denosumab, alendronic acid show null effect on aortic valve calcification

Denosumab, alendronic acid show null effect on aortic valve calcification

Hormonal IUD shows potential in early endometrial cancer

Hormonal IUD shows potential in early endometrial cancer

Severe QT prolongation rare with bedaquiline-based treatment for drug-resistant TB

Severe QT prolongation rare with bedaquiline-based treatment for drug-resistant TB

Apatinib-pegylated liposomal doxorubicin combo ups survival in ovarian cancer

Apatinib-pegylated liposomal doxorubicin combo ups survival in ovarian cancer

ORZORA: Maintenance olaparib shows benefit in BRCA-mutated ovarian cancer

ORZORA: Maintenance olaparib shows benefit in BRCA-mutated ovarian cancer